Key takeaways
- L'Oreal confirmed GLP-1 weight loss is shifting global beauty and skincare demands.
- Brands like SkinCeuticals and Kiehl's are designing products specifically to treat skin sagging.
- L'Oreal's partner Galderma is testing injectables like Sculptra specifically on GLP-1 patients.
- Aesthetic treatments for 'Ozempic face' can add thousands in unexpected out-of-pocket costs for telehealth patients.
What happened
In a third-quarter investor call, L'Oreal Chief Executive Officer Nicolas Hieronimus confirmed that the rapid rise of GLP-1 weight-loss medications is actively reshaping global beauty and skincare consumption. To address this shifting demand, the world's largest cosmetics company has begun targeting the side effects of rapid weight loss—specifically skin sagging—by designing and promoting specialized products through its clinical skincare brands.
Why it matters
For patients utilizing online telehealth platforms to access weight-loss medications like Wegovy, Zepbound, or compounded alternatives, the physical transformation often brings an unexpected financial burden. Rapid fat loss can deplete facial volume and leave behind loose, sagging skin—a phenomenon colloquially dubbed "Ozempic face."
As consumer demand shifts, major beauty and dermatology conglomerates are stepping in with high-end, targeted treatments. However, these clinical skincare regimens and aesthetic procedures introduce significant, ongoing out-of-pocket costs. Patients budgeting for their monthly telehealth subscriptions must now consider the secondary costs of maintaining skin elasticity and facial volume, which can easily rival or exceed the price of the medications themselves.
What the data says
According to L'Oreal's third-quarter financial report, the company's overall sales grew by 7.7% in the three months ending in September, beating analyst expectations. During the investor presentation, Hieronimus highlighted GLP-1 adoption as "a very important phenomenon for us" that is directly influencing consumer spending on skincare.
To capitalize on this trend, L'Oreal is leveraging medical-grade brands like SkinCeuticals and Kiehl's to market products engineered to work alongside weight-loss treatments. Additionally, L'Oreal expanded its presence in the clinical dermatology market by acquiring a 20% stake in Galderma.
Galderma, which manufactures the collagen-stimulating injectable Sculptra and the dermal filler Restylane, has actively researched this patient demographic. In separate clinical trials, both L'Oreal and Galderma have been testing products specifically on GLP-1 users. A survey conducted by Galderma revealed that the vast majority of patients using weight-loss medications noticed visible changes to their facial appearance, driving interest in corrective aesthetic procedures.
How it compares
The secondary cost of managing "GLP-1 face" highlights a stark contrast in patient spending:
- The Medication Baseline: Monthly costs for brand-name GLP-1s average $900 to $1,300 without insurance, while compounded semaglutide through popular telehealth providers generally ranges from $200 to $400 per month.
- The Skincare Premium: High-end clinical topical serums from brands like SkinCeuticals frequently retail for $150 to $200 per bottle.
- The Aesthetic Injectable Jump: For severe volume loss, topical creams are rarely sufficient. Clinical injectables like Galderma's Sculptra or Restylane must be administered by a licensed provider and typically cost between $800 and $1,600 per treatment session. Because multiple sessions are required to build collagen, patients can easily face an additional $3,000 to $5,000 in yearly aesthetic maintenance.
While generic or compounded medications offer a way to save on the upfront cost of treatment, the cosmetic side effects of rapid weight loss can quickly erase those savings if patients choose to address skin laxity through premium clinical channels.
How this fits the bigger picture
This development highlights how the GLP-1 boom is generating a massive secondary economy, stretching far beyond the pharmaceutical sector. We have previously tracked how rapid weight loss alters patient lifestyle needs, from apparel shopping to diet modification. L'Oreal's strategic pivot proves that the cosmetic and dermatological industries are now formalizing "GLP-1 companion" product lines as a permanent category.
This shift mirrors other market corrections driven by next-generation weight-loss therapies. For example, as manufacturers develop highly potent next-generation compounds—such as Novo Nordisk's CagriSema, which drove historic weight loss in clinical trials as discussed in our coverage of /news/novo-cagrisema-drives-25-percent-weight-loss-women—the speed and scale of patient fat loss will only increase. Similarly, Eli Lilly’s pipeline candidate retatrutide has demonstrated unprecedented weight reduction in Phase III trials, which we analyzed in /news/lilly-retatrutide-triumph2-diabetes-weight-loss-benchmark.
As these highly effective, multi-receptor therapies eventually reach the market, the physical side effects of rapid fat depletion, such as skin sagging, will become even more common. Consequently, the demand for clinical skincare and collagen-stimulating injectables is poised to transition from a niche luxury market into a mainstream accompaniment to medical weight loss.
What happens next
L'Oreal and Galderma are expected to release more detailed data from their ongoing clinical trials evaluating topical and injectable treatments specifically in patients using GLP-1 medications. As these studies conclude, consumers can expect a wave of targeted marketing campaigns and product launches specifically branded as "GLP-1 companion skincare."
In the meantime, patients exploring medical weight loss should evaluate their budgets holistically. When comparing options on our /providers directory, it is wise to factor in the potential secondary costs of dermatological care and skin support alongside the base price of the medication.
Disclaimer: CompareRx does not provide medical advice. Always consult with a licensed healthcare provider before starting any weight-loss medication or undergoing clinical aesthetic treatments.